These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 19077768)
1. Cardiovascular effects of thiazolidinediones: a review of the literature. Acharya D; Falik R South Med J; 2009 Jan; 102(1):51-6. PubMed ID: 19077768 [TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Defronzo RA; Mehta RJ; Schnure JJ Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744 [TBL] [Abstract][Full Text] [Related]
3. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. Hiatt WR; Kaul S; Smith RJ N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603 [No Abstract] [Full Text] [Related]
4. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart. Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888 [No Abstract] [Full Text] [Related]
5. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
6. The safety of thiazolidinediones. Tolman KG Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501 [TBL] [Abstract][Full Text] [Related]
8. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Patel C; Wyne KL; McGuire DK Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060 [TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes? Vaccaro O; Riccardi G Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715 [No Abstract] [Full Text] [Related]
11. Rosiglitazone and cardiovascular risk. Mannucci E; Monami M; Marchionni N N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136 [No Abstract] [Full Text] [Related]
13. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ; J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044 [No Abstract] [Full Text] [Related]
14. [Heart failure with thiazolidinedione treatment: what do we know today?]. Erdmann E Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858 [TBL] [Abstract][Full Text] [Related]
15. [Glitazone - mailing no 3. In response to DMW 49/2007]. Gundel UF Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354 [No Abstract] [Full Text] [Related]
16. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Patel RR Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087 [TBL] [Abstract][Full Text] [Related]